Artificial Intelligence in Drug Discovery Market - Trends, Size & Outlook (2024-2032)

Artificial Intelligence in Drug Discovery Market Synopsis:

Artificial Intelligence in Drug Discovery Market Size Was Valued at USD 2.13 Billion in 2023, and is Projected to Reach USD 22.70 Billion by 2032, Growing at a CAGR of 30.07% From 2024-2032.

The Artificial Intelligence in Drug Discovery Market is defined as the application of Artificial Intelligence and machine learning for improving the process and productivity of drug discovery. This covers such areas as identification of compounds with potential therapeutic efficacy to enhancement of their effectiveness and decrease of their toxicity so that less expenditure and time is used as compared to conventional drug discovery processes.

Artificial intelligence (AI) has now appeared in the sphere of drug discovery and development and its impact is revolutionary, bringing high speed and new opportunities. AI methods allow processing a large amount of data coming from different data sources such as genomics, clinical data, and biological processes. Three areas where robotic technologies can benefit research and discovery are the identification of targets for the drug, prediction of the reaction of target molecules, and selection of the best leads. For extending knowledge of increasing biological systems’, complication and necessity of new drugs development of the rapid pace as a result of the COVID-19 pandemic, AI is evolving in this sphere.

Consequently, the growth of the AI in drug discovery market is gradually increasing as a result of increased computing power and ability to analyze big data, greater development of algorithms. New AI technologies have become hot favourite among major pharmaceutical corporates and biotechnology enterprises to accelerate drug discovery and bring more new and better therapies to the market faster. Of special interest is the growing number of technology companies and healthcare organizations partnering to develop new platforms and solutions that leverage AI in drug discovery. This constantly developing market will be of huge significance for development of molecular medicine acting as a base for creating different treatments depending on a person’s genes.

Artificial Intelligence in Drug Discovery Market Trend Analysis:

Increased Adoption of Machine Learning Algorithms

• The growth of sophisticated and complex application is expected to become a major factor for the market for artificial intelligence in drug discovery. Machine learning models can be used to analyse big data as well as patterns which might be unnoticed by a researcher. This capability means that effective drug candidates can can be identified quickly thus improving the efficiency of the drug discovery process. With the help of the advanced algorithms, researchers can make inference about the compounds’ behavior, estimate their toxicity or change the lead candidates by the given criteria, which in turn, paves the way for the faster drug discovery process.
• Furthermore, with the constant advancement in machine learning engineering, the efficiency in prediction and conclusion drawn in drug discovery is improving. Although it remains to be seen how rapidly data availability will grow and how soon computational power will increase, the incorporation of machine learning appears to be the future of the industry. It is believed that the higher number of drug candidates will successfully pass into clinical phase and this will in turn enhance the achievement rate of drug finding processes.

Growth in Personalized Medicine

• The greatest potential for AI in the drug discovery and development market may be seen in the development of personalized medicine. As the human body keeps on being sequenced, together with the potential ailments determined by genetic differences and the resultant treatment effects, AI should be instrumental in designing personalized medication assembled in the direction of the critical specifications of the patient. Using AI tools, researchers and engineers can learn about the genomes of patients and look for patterns which inform whether a certain therapy will work or not, leading to the creation of drugs that are most efficient and non-harmful for certain population groups.
• In addition, customization of treatment has appealed to the increasing preferences towards more targeted therapies that are relevant to patients’ individual profile. As patient-centred care models are being adopted for modern healthcare organisations, AI-based drug discovery platforms would prove critical in filling this gap. There is great potential for companies to enhance AI-assisted therapeutic development to help improve patient prognosis and make healthcare administration more efficient since this chance has the potential to increase the value created by players in this space significantly.

Artificial Intelligence in Drug Discovery Market Segment Analysis:

Artificial Intelligence in Drug Discovery Market is Segmented on the basis of Application, Therapeutic Area, and Region

By Therapeutic Area, Neurodegenerative Diseases segment is expected to dominate the market during the forecast period

• The artificial intelligence in the drug discovery market comprises different therapeutic areas that are promising and complex in many ways. Cancer care is one of the most active fields for AI application, and many researchers are using AI algorithms to analyze genes and molecules and to look for new drug targets or estimate response to some treatments. Due to the fact that cancer is a multifaceted disease and patient treatment should be more individualized, application of AI become crucial for finding new therapy techniques which can enhance patients’ lives.
• Other chronic diseases are also suitable for AI, since machine learning provides insights into the development of neurodegenerative diseases as Alzheimer’s or Parkinson’s. In large dataset of clinical trials & patient data AI enables finding biomarkers & prognosis of the disease so that better treatments can be administered. Thus, in cardiovascular diseases, AI-based analysis can improve the identification of drugs to contribute to the treatment of particular risk factors and individual patients. The need for efficient treatments in such therapeutic areas remains a major factor that fuels the use of AI in drug discovery.

By Application, Preclinical testing segment expected to held the largest share

• Currently, technology solution areas in the artificial intelligence in drug discovery market involves drug optimization, repurposing among others. Existing structures and data on drugs can be analyzed through AI algorithms in a bid to find new purposes for approved drugs greatly reducing the amount of time spent on drug discovery. The concept of using a new indication for an existing drug based off a new discovery is advantageous because the manufacturer will not have to start all over with the process of creating an entirely new compound to ensure that it is safe when used for the new discovered indication. It is especially effective in response to emergent health needs, for example, the development of interventions in response to public health concerns.
• Another essential application that is seen to gain significantly from the incorporation of AI is Preclinical testing. AI technologies help analyze the preclinical data, and therefore it becomes possible to understand how new compounds will perform on man. This decision-making or prediction capacity improves the choices of the lead compounds and the transfer to the clinic phases. With the growing desire of the pharmaceutical industry to enhance the efficiency of their preclinical processes AI is expanding its applications in terms of test protocols and data analysis.

Artificial Intelligence in Drug Discovery Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• In the current market, the largest revenue is in North America because of its leading industry in pharmaceuticals and biotechnology. Chemicals can truly be regarded as Indiana’s ‘liquid assets’, as the state boasts well developed pharmaceuticals manufacturing sector together with highly acclaimed research institutions as well as technology companies thus directing the development of the chemical subsector towards innovation and cooperative working. Furthermore, the area enjoys high investment in developing HC technology and AI applications that augment drug development processes. North America most countries also have well-proven regulatory systems, which forms the best environment for implementation of AI in drug development.
• In addition, the changing healthcare approach towards patient-specific medicine and pressure to deliver more drugs swiftly due to contemporary diseases like COVID-19 have influenced AI’s usage in North America. The commitment to improving the health care and drug discovery has put the region as a frontrunner in the market for artificial intelligence in drug discovery. These investments are likely to rise further, partnering relationships also to widen, North America is foreseen to sustain its supremacy in this rapidly emerging market.

Active Key Players in the Artificial Intelligence in Drug Discovery Market:

• Atomwise (USA)
• BenevolentAI (UK)
• Insilico Medicine (USA)
• Berg Health (USA)
• Recursion Pharmaceuticals (USA)
• NVIDIA (USA)
• Exscientia (UK)
• Biorelate (UK)
• 1drop (USA)
• Tempus (USA)
• CureMetrix (USA)
• Enveda Biosciences (USA)
• Other Active Players

Key Industry Developments in the Artificial Intelligence in Drug Discovery Market:

• In May 2024, Google DeepMind released the third version of its AlphaFold AI-based model, aimed at advancing drug design and disease targeting. This latest iteration allows researchers at DeepMind and Isomorphic Labs to map the behavior of all molecules, including human DNA.
• In April 2024, Xaira Therapeutics, an AI-powered drug discovery and development company, raised over USD 1 Million in a joint funding round with ARCH Venture Partners and Foresite Labs. The company uses machine learning, data generation models, and therapeutic product development to target traditionally challenging drug targets
• In December 2023, MilliporeSigma, the life science division of Merck, introduced AIDDISON, an innovative drug discovery software. This tool aims to seamlessly connect the design of virtual molecules with practical manufacturability. It leverages the Synthia retrosynthesis software API to enhance the efficiency and feasibility of drug development processes
• In May 2023, Google introduced two new AI-powered solutions designed to assist biotech and pharmaceutical companies in expediting drug discovery and advancing precision medicine. These tools aim to streamline the lengthy and costly process of bringing new treatments to the U.S. market. Cerevel Therapeutics, Pfizer, and Colossal Biosciences are among the early adopters of these solutions.